Abstract
In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
| Original language | English |
|---|---|
| Pages (from-to) | 198-203 |
| Number of pages | 6 |
| Journal | Leukemia Research |
| Volume | 38 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2014 |
Fingerprint
Keywords
- Alemtuzumab
- Biology
- Chronic lymphocytic leukemia
- CLL
- Fludarabine
- Young
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
- Medicine(all)
Cite this
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. / Mauro, Francesca R.; Molica, Stefano; Laurenti, Luca; Cortelezzi, Agostino; Carella, Angelo M.; Zaja, Francesco; Chiarenza, Annalisa; Angrilli, Francesco; Nobile, Francesco; Marasca, Roberto; Musolino, Caterina; Brugiatelli, Maura; Piciocchi, Alfonso; Vignetti, Marco; Fazi, Paola; Gentile, Giuseppe; De Propris, Maria S.; Starza, Irene Della; Marinelli, Marilisa; Chiaretti, Sabina; Del Giudice, Ilaria; Nanni, Mauro; Albano, Francesco; Cuneo, Antonio; Guarini, Anna; Foà, Robin.
In: Leukemia Research, Vol. 38, No. 2, 02.2014, p. 198-203.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
AU - Mauro, Francesca R.
AU - Molica, Stefano
AU - Laurenti, Luca
AU - Cortelezzi, Agostino
AU - Carella, Angelo M.
AU - Zaja, Francesco
AU - Chiarenza, Annalisa
AU - Angrilli, Francesco
AU - Nobile, Francesco
AU - Marasca, Roberto
AU - Musolino, Caterina
AU - Brugiatelli, Maura
AU - Piciocchi, Alfonso
AU - Vignetti, Marco
AU - Fazi, Paola
AU - Gentile, Giuseppe
AU - De Propris, Maria S.
AU - Starza, Irene Della
AU - Marinelli, Marilisa
AU - Chiaretti, Sabina
AU - Del Giudice, Ilaria
AU - Nanni, Mauro
AU - Albano, Francesco
AU - Cuneo, Antonio
AU - Guarini, Anna
AU - Foà, Robin
PY - 2014/2
Y1 - 2014/2
N2 - In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
AB - In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
KW - Alemtuzumab
KW - Biology
KW - Chronic lymphocytic leukemia
KW - CLL
KW - Fludarabine
KW - Young
UR - http://www.scopus.com/inward/record.url?scp=84892510314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892510314&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2013.11.009
DO - 10.1016/j.leukres.2013.11.009
M3 - Article
C2 - 24314589
AN - SCOPUS:84892510314
VL - 38
SP - 198
EP - 203
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 2
ER -